ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
97,039.41
2.84%
S&P 500
5,921.62
0.08%
Dow Jones
43,591.13
0.42%
US Dollar vs Yen
154.07
-0.79%
Brent Oil
73.665
1.13%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. イギリス
  5. LSE

  6. Bergenbio Asa (0RU5) 銘柄情報

Bergenbio Asa

Bergenbio Asa (0RU5)

LSE
4,600.00
0.00
( 0.00% )
更新日時： 09:00:00
15分遅延

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
4,600.00
買値
0.00
売値
0.00
出来高
1,716
0.00 日の範囲 0.00
4,600.00 52 週間の範囲 4,600.00
時価総額
12.368T
前日終値
4,600.00
始値
-
時刻
1000
@
9.675
(O)
最終取引時間
18:36:36
財務取引量
-
VWAP
-
平均取引量 (3 か月)
722
発行済株式数
2,688,689,000
配当利回り
-
PER
-64,971.75
1 株当たり利益 (EPS)
-0.07
歳入
354k
純利益
-190.4M

Bergenbio Asa について

セクター
Meas & Controlling Dev, Nec
業界
Meas & Controlling Dev, Nec
ウェブサイト
www.bergenbio.com
本社
Bergen, Nor
設立
-
Bergenbio Asa is listed in the Meas & Controlling Dev sector of the ロンドン証券取引所 with ticker 0RU5. The last closing price for Bergenbio Asa was kr4,600. Over the last year, Bergenbio Asa shares have traded in a share price range of kr 4,600.00 to kr 4,600.00.

Bergenbio Asa currently has 2,688,689,000 shares in issue. The market capitalisation of Bergenbio Asa is kr12.37 trillion. Bergenbio Asa has a price to earnings ratio (PE ratio) of -64971.75.

0RU5 最新ニュース

その他のニュース

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

19時間前
PR Newswire (US)

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

19時間前
PR Newswire (US)

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

2023年8月22日
PR Newswire (US)

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

2023年8月22日
PR Newswire (US)

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR...

2023年5月26日
PR Newswire (US)

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...

2023年4月26日
PR Newswire (US)

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

2023年4月18日
PR Newswire (US)

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

2023年4月18日
PR Newswire (US)

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

2023年3月9日
PR Newswire (US)

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

2023年3月9日
PR Newswire (US)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10046004600460017884600DE
40046004600460012774600DE
12004600460046007224600DE
260046004600460024404600DE
5200460046004600908494600DE
15600460046004600772544600DE
26000460046004600481534600DE

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
FARFerro-alloy Resources Limited
5.45p
(131.91%)
30.19M
VELAVela Technologies Plc
0.0075p
(36.36%)
208.9M
ROCRockpool Acquisitions Plc
2.25p
(28.57%)
150k
RCGHRc365 Holding Plc
1.60p
(28.00%)
2.96M
CASPCaspian Sunrise Plc
3.45p
(23.21%)
10M
NTOGNostra Terra Oil And Gas Company Plc
0.0235p
(-37.33%)
774.7M
SLFRSlf Realisation Fund Limited
1.02p
(-27.66%)
293.37k
QUIZQuiz Plc
4.02p
(-23.43%)
18.99k
PPSProton Motor Power Systems Plc
0.145p
(-19.44%)
5.46M
KP2Kore Potash Plc
2.45p
(-18.33%)
6.87M
NTOGNostra Terra Oil And Gas Company Plc
0.0235p
(-37.33%)
774.7M
NTVONativo Resources Plc
0.0023p
(0.00%)
517.61M
TRPTower Resources Plc
0.028p
(1.82%)
449.25M
HAYDHaydale Graphene Industries Plc
0.115p
(0.00%)
266.81M
MSMNMosman Oil And Gas Limited
0.04p
(0.00%)
227.17M

議論

フィード全体を表示

最近閲覧した銘柄

LSE
0RU5
Bergenbio Asa
LSE
CRPR
Cropper (james)
ASX
AVR
Anteris Technologies
NASDAQ
EA
Electronic Arts
LSE
RCDO
Ricardo
NYSE
ECO
Okeanis Eco Tankers
USOTC
ARESF
Artis Real Estate Invest... (QX)
USOTC
AGBIF
Atlas Global Brands (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有